Mutation of a single envelope N-linked glycosylation site enhances the pathogenicity of bovine leukemia virus

Journal of Virology

Volumn 89, Issue 17, 2015, Pages 8945-8956

  de Brogniez, Alix ^a   Bouzar, Amel Baya ^a   Jacques, Jean Rock ^a   Cosse, Jean Philippe ^a   Gillet, Nicolas ^a   Callebaut, Isabelle ^b   Reichert, Michal ^c   Willems, Luc ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b SORBONNE UNIVERSITÉ   (France)

^c NATIONAL VETERINARY RESEARCH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BOVINE LEUKEMIA VIRUS; CONTROLLED STUDY; EMBRYO; ENZYME GLYCOSYLATION; ENZYME METABOLISM; HUMAN; HUMAN CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; SHEEP; SITE DIRECTED MUTAGENESIS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS VIRULENCE; AMINO ACID SEQUENCE; ANIMAL; CAT; CELL FUSION; CHLOROCEBUS AETHIOPS; COS CELL LINE; GENETICS; GLYCOSYLATION; HEK293 CELL LINE; HELA CELL LINE; MEMBRANE FUSION; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PROTEIN STABILITY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; VIRUS LOAD;

BOVINE LEUKEMIA VIRUS;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CATS; CELL FUSION; CERCOPITHECUS AETHIOPS; COS CELLS; GLYCOSYLATION; HEK293 CELLS; HELA CELLS; HUMANS; LEUKEMIA VIRUS, BOVINE; MEMBRANE FUSION; MUTATION; PROTEIN STABILITY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, RNA; SHEEP; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84938910667     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00261-15     Document Type: Article

References (64)

1. Rodriguez SM, Florins A, Gillet N, de Brogniez A, Sanchez-Alcaraz MT, Boxus M, Boulanger F, Gutierrez G, Trono K, Alvarez I, Vagnoni L, Willems L. 2011. Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV. Viruses 3:1210-1248. http://dx.doi.org/10.3390/v3071210.
2. Kchour G, Rezaee R, Farid R, Ghantous A, Rafatpanah H, Tarhini M, Kooshyar MM, El Hajj H, Berry F, Mortada M, Nasser R, Shirdel A, Dassouki Z, Ezzedine M, Rahimi H, Ghavamzadeh A, de The H, Hermine O, Mahmoudi M, Bazarbachi A. 2013. The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology 10:91. http://dx.doi.org/10.1186/1742-4690-10-91.
3. Erskine RJ, Bartlett PC, Byrem TM, Render CL, Febvay C, Houseman JT. 2012. Association between bovine leukemia virus, production, and population age in Michigan dairy herds. J Dairy Sci 95:727-734. http://dx.doi.org/10.3168/jds.2011-4760.
4. Ferrer JF, Abt DA, Bhatt DM, Marshak RR. 1974. Studies on the relationship between infection with bovine C-type virus, leukemia, and persistent lymphocytosis in cattle. Cancer Res 34:893-900.
5. Gatei MH, Brandon R, Naif HM, Lavin MF, Daniel RC. 1989. Lymphosarcoma development in sheep experimentally infected with bovine leukaemia virus. Zentralbl Veterinarmed B 36:424-432.
6. Mammerickx M, Portetelle D, Burny A. 1981. Experimental crosstransmissions of bovine leukemia virus (BLV) between several animal species. Zentralbl Veterinarmed B 28:69-81.
7. Olson C, Kettmann R, Burny A, Kaja R. 1981. Goat lymphosarcoma from bovine leukemia virus. J Natl Cancer Inst 67:671-675.
8. Mamoun RZ, Morisson M, Rebeyrotte N, Busetta B, Couez D, Kettmann R, Hospital M, Guillemain B. 1990. Sequence variability of bovine leukemia virus env gene and its relevance to the structure and antigenicity of the glycoproteins. J Virol 64:4180-4188.
9. Dietzschold B, Kaaden OR, Frenzel B. 1978. Subunit and fine structure of the glycoprotein of bovine leukemia virus. Ann Rech Vet 9:613-617.
10. Ghysdael J, Kettmann R, Burny A. 1979. Translation of bovine leukemia virus virion RNAs in heterologous protein-synthesizing systems. J Virol 29:1087-1098.
11. Mamoun RZ, Astier T, Guillemain B, Duplan JF. 1983. Bovine lymphosarcoma: processing of bovine leukaemia virus-coded proteins. J Gen Virol 64(Pt 12):2791-2795.
12. Helenius A, Aebi M. 2004. Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem 73:1019-1049. http://dx.doi.org/10.1146/annurev.biochem.73.011303.073752.
13. Doms RW, Lamb RA, Rose JK, Helenius A. 1993. Folding and assembly of viral membrane proteins. Virology 193:545-562. http://dx.doi.org/10.1006/viro.1993.1164.
14. Aguilar HC, Matreyek KA, Filone CM, Hashimi ST, Levroney EL, Negrete OA, Bertolotti-Ciarlet A, Choi DY, McHardy I, Fulcher JA, Su SV, Wolf MC, Kohatsu L, Baum LG, Lee B. 2006. N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol 80:4878-4889. http://dx.doi.org/10.1128/JVI.80.10.4878-4889.2006.
15. Olofsson S, Hansen JE. 1998. Host cell glycosylation of viral glycoproteins: a battlefield for host defence and viral resistance. Scand J Infect Dis 30:435-440. http://dx.doi.org/10.1080/00365549850161386.
16. von Messling V, Cattaneo R. 2003. N-linked glycans with similar location in the fusion protein head modulate paramyxovirus fusion. J Virol 77: 10202-10212. http://dx.doi.org/10.1128/JVI.77.19.10202-10212.2003.
17. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. http://dx.doi.org/10.1038/nature01470.
18. Pikora CA. 2004. Glycosylation of the ENV spike of primate immunodeficiency viruses and antibody neutralization. Curr HIV Res 2:243-254. http://dx.doi.org/10.2174/1570162043351264.
19. Polzer S, Dittmar MT, Schmitz H, Meyer B, Muller H, Krausslich HG, Schreiber M. 2001. Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1. Glycobiology 11:11-19. http://dx.doi.org/10.1093/glycob/11.1.11.
20. Reitter JN, Means RE, Desrosiers RC. 1998. A role for carbohydrates in immune evasion in AIDS. Nat Med 4:679-684. http://dx.doi.org/10.1038/nm0698-679.
21. Willems L, Grimonpont C, Heremans H, Rebeyrotte N, Chen G, Portetelle D, Burny A, Kettmann R. 1992. Mutations in the bovine leukemia virus Tax protein can abrogate the long terminal repeat-directed transactivating activity without concomitant loss of transforming potential. Proc Natl Acad Sci U S A 89:3957-3961. http://dx.doi.org/10.1073/pnas.89.9.3957.
22. Green S, Issemann I, Sheer E. 1988. A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res 16:369. http://dx.doi.org/10.1093/nar/16.1.369.
23. Willems L, Portetelle D, Kerkhofs P, Chen G, Burny A, Mammerickx M, Kettmann R. 1992. In vivo transfection of bovine leukemia provirus into sheep. Virology 189:775-777. http://dx.doi.org/10.1016/0042-6822(92)90604-N.
24. Gillet NA, Gutierrez G, Rodriguez SM, de Brogniez A, Renotte N, Alvarez I, Trono K, Willems L. 2013. Massive depletion of bovine leukemia virus proviral clones located in genomic transcriptionally active sites during primary infection. PLoS Pathog 9:e1003687. http://dx.doi.org/10.1371/journal.ppat.1003687.
25. Inabe K, Ikuta K, Aida Y. 1998. Transmission and propagation in cell culture of virus produced by cells transfected with an infectious molecular clone of bovine leukemia virus. Virology 245:53-64. http://dx.doi.org/10.1006/viro.1998.9140.
26. Pique C, Pham D, Tursz T, Dokhelar MC. 1992. Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation. J Virol 66:906-913.
27. Eckert DM, Kim PS. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70:777-810. http://dx.doi.org/10.1146/annurev.biochem.70.1.777.
28. Jardetzky TS, Lamb RA. 2014. Activation of paramyxovirus membrane fusion and virus entry. Curr Opin Virol 5:24-33. http://dx.doi.org/10.1016/j.coviro.2014.01.005.
29. McGinnes LW, Morrison TG. 1995. The role of individual oligosaccharide chains in the activities of the HN glycoprotein of Newcastle disease virus. Virology 212:398-410. http://dx.doi.org/10.1006/viro.1995.1497.
30. Florins A, Reichert M, Asquith B, Bouzar AB, Jean G, Francois C, Jasik A, Burny A, Kettmann R, Willems L. 2009. Earlier onset of deltaretrovirus-induced leukemia after splenectomy. PLoS One 4:e6943. http://dx.doi.org/10.1371/journal.pone.0006943.
31. Francois KO, Balzarini J. 2011. The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J Biol Chem 286: 42900-42910. http://dx.doi.org/10.1074/jbc.M111.274456.
32. Leikina E, Delanoe-Ayari H, Melikov K, Cho MS, Chen A, Waring AJ, Wang W, Xie Y, Loo JA, Lehrer RI, Chernomordik LV. 2005. Carbohydrate-binding molecules inhibit viral fusion and entry by cross-linking membrane glycoproteins. Nat Immunol 6:995-1001. http://dx.doi.org/10.1038/ni1248.
33. Pollicita M, Schols D, Aquaro S, Peumans WJ, Van Damme EJ, Perno CF, Balzarini J. 2008. Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes. Virology 370:382-391. http://dx.doi.org/10.1016/j.virol.2007.08.033.
34. Balestrieri E, Ascolani A, Igarashi Y, Oki T, Mastino A, Balzarini J, Macchi B. 2008. Inhibition of cell-to-cell transmission of human T-cell lymphotropic virus type 1 in vitro by carbohydrate-binding agents. Antimicrob Agents Chemother 52:2771-2779. http://dx.doi.org/10.1128/AAC.01671-07.
35. Matthews TJ, Weinhold KJ, Lyerly HK, Langlois AJ, Wigzell H, Bolognesi DP. 1987. Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A 84:5424-5428. http://dx.doi.org/10.1073/pnas.84.15.5424.
36. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 2:1244-1247. http://dx.doi.org/10.1038/nm1196-1244.
37. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. 2000. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 74:1961-1972. http://dx.doi.org/10.1128/JVI.74.4.1961-1972.2000.
38. Bruck C, Portetelle D, Burny A, Zavada J. 1982. Topographical analysis by monoclonal antibodies of BLV-gp51 epitopes involved in viral functions. Virology 122:353-362. http://dx.doi.org/10.1016/0042-6822(82)90235-5.
39. Bruck C, Rensonnet N, Portetelle D, Cleuter Y, Mammerickx M, Burny A, Mamoun R, Guillemain B, van der Maaten MJ, Ghysdael J. 1984. Biologically active epitopes of bovine leukemia virus glycoprotein gp51: their dependence on protein glycosylation and genetic variability. Virology 136:20-31. http://dx.doi.org/10.1016/0042-6822(84)90244-7.
40. Balzarini J, Hatse S, Vermeire K, Princen K, Aquaro S, Perno CF, De Clercq E, Egberink H, Vanden Mooter G, Peumans W, Van Damme E, Schols D. 2004. Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother 48:3858-3870. http://dx.doi.org/10.1128/AAC.48.10.3858-3870.2004.
41. Balzarini J, Van Laethem K, Daelemans D, Hatse S, Bugatti A, Rusnati M, Igarashi Y, Oki T, Schols D. 2007. Pradimicin A, a carbohydratebinding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. J Virol 81:362-373. http://dx.doi.org/10.1128/JVI.01404-06.
42. Rola-Luszczak M, Pluta A, Olech M, Donnik I, Petropavlovskiy M, Gerilovych A, Vinogradova I, Choudhury B, Kuzmak J. 2013. The molecular characterization of bovine leukaemia virus isolates from Eastern Europe and Siberia and its impact on phylogeny. PLoS One 8:e58705. http://dx.doi.org/10.1371/journal.pone.0058705.
43. Albers JJ, Day JR, Wolfbauer G, Kennedy H, Vuletic S, Cheung MC. 2011. Impact of site-specific N-glycosylation on cellular secretion, activity and specific activity of the plasma phospholipid transfer protein. Biochim Biophys Acta 1814:908-911. http://dx.doi.org/10.1016/j.bbapap.2011.04.004.
44. Panda A, Elankumaran S, Krishnamurthy S, Huang Z, Samal SK. 2004. Loss of N-linked glycosylation from the hemagglutinin-neuraminidase protein alters virulence of Newcastle disease virus. J Virol 78:4965-4975. http://dx.doi.org/10.1128/JVI.78.10.4965-4975.2004.
45. Moll M, Kaufmann A, Maisner A. 2004. Influence of N-glycans on processing and biological activity of the Nipah virus fusion protein. J Virol 78:7274-7278. http://dx.doi.org/10.1128/JVI.78.13.7274-7278.2004.
46. Nakayama EE, Shioda T, Tatsumi M, Xin X, Yu D, Ohgimoto S, Kato A, Sakai Y, Ohnishi Y, Nagai Y. 1998. Importance of the N-glycan in theV3loop ofHIV-1 envelope protein for CXCR-4-but not CCR-5-dependent fusion. FEBS Lett 426: 367-372. http://dx.doi.org/10.1016/S0014-5793(98)00375-5.
47. Losman B, Biller M, Olofsson S, Schonning K, Lund OS, Svennerholm B, Hansen JE, Bolmstedt A. 1999. The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. FEBS Lett 454: 47-52. http://dx.doi.org/10.1016/S0014-5793(99)00740-1.
48. White JM, Delos SE, Brecher M, Schornberg K. 2008. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 43:189-219. http://dx.doi.org/10.1080/10409230802058320.
49. Lamb D, Schuttelkopf AW, van Aalten DM, Brighty DW. 2008. Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope. Retrovirology 5:70. http://dx.doi.org/10.1186/1742-4690-5-70.
50. Samal S, Khattar SK, Kumar S, Collins PL, Samal SK. 2012. Coordinate deletion of N-glycans from the heptad repeats of the fusion F protein of Newcastle disease virus yields a hyperfusogenic virus with increased replication, virulence, and immunogenicity. J Virol 86:2501-2511. http://dx.doi.org/10.1128/JVI.06380-11.
51. Biering SB, Huang A, Vu AT, Robinson LR, Bradel-Tretheway B, Choi E, Lee B, Aguilar HC. 2012. N-glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization. J Virol 86:11991-12002. http://dx.doi.org/10.1128/JVI.01304-12.
52. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R. 2003. The HIV Env-mediated fusion reaction. Biochim Biophys Acta 1614:36-50. http://dx.doi.org/10.1016/S0005-2736(03)00161-5.
53. Abrahamyan LG, Mkrtchyan SR, Binley J, Lu M, Melikyan GB, Cohen FS. 2005. The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the sixhelix bundle. J Virol 79:106-115. http://dx.doi.org/10.1128/JVI.79.1.106-115.2005.
54. Pomier C, Alcaraz MT, Debacq C, Lancon A, Kerkhofs P, Willems L, Wattel E, Mortreux F. 2008. Early and transient reverse transcription during primary deltaretroviral infection of sheep. Retrovirology 5:16. http://dx.doi.org/10.1186/1742-4690-5-16.
55. Mortreux F, Kazanji M, Gabet AS, de Thoisy B, Wattel E. 2001. Two-step nature of human T-cell leukemia virus type 1 replication in experimentally infected squirrel monkeys (Saimiri sciureus). J Virol 75: 1083-1089. http://dx.doi.org/10.1128/JVI.75.2.1083-1089.2001.
56. Gatot JS, Callebaut I, Mornon JP, Portetelle D, Burny A, Kerkhofs P, Kettmann R, Willems L. 1998. Conservative mutations in the immunosuppressive region of the bovine leukemia virus transmembrane protein affect fusion but not infectivity in vivo. J Biol Chem 273:12870-12880. http://dx.doi.org/10.1074/jbc.273.21.12870.
57. Merezak C, Pierreux C, Adam E, Lemaigre F, Rousseau GG, Calomme C, Van Lint C, Christophe D, Kerkhofs P, Burny A, Kettmann R, Willems L. 2001. Suboptimal enhancer sequences are required for efficient bovine leukemia virus propagation in vivo: implications for viral latency. J Virol 75:6977-6988. http://dx.doi.org/10.1128/JVI.75.15.6977-6988.2001.
58. Okada K, Nakae N, Kuramochi K, Yin SA, Ikeda M, Takami S, Hirata T, Goryo M, Numakunai S, Takeshima SN, Takahashi M, Tajima S, Konnai S, Onuma M, Aida Y. 2005. Bovine leukemia virus high tax molecular clone experimentally induces leukemia/lymphoma in sheep. J Vet Med Sci 67:1231-1235. http://dx.doi.org/10.1292/jvms.67.1231.
59. Callebaut I, Labesse G, Durand P, Poupon A, Canard L, Chomilier J, Henrissat B, Mornon JP. 1997. Deciphering protein sequence information through hydrophobic cluster analysis (HCA): current status and perspectives. Cell Mol Life Sci 53:621-645. http://dx.doi.org/10.1007/s000180050082.
60. Woodcock S, Mornon JP, Henrissat B. 1992. Detection of secondary structure elements in proteins by hydrophobic cluster analysis. Protein Eng 5:629-635. http://dx.doi.org/10.1093/protein/5.7.629.
61. Gatot JS, Callebaut I, Van Lint C, Demonte D, Kerkhofs P, Portetelle D, Burny A, Willems L, Kettmann R. 2002. Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo. J Virol 76:7956-7967. http://dx.doi.org/10.1128/JVI.76.16.7956-7967.2002.
62. Eudes R, Le Tuan K, Delettre J, Mornon JP, Callebaut I. 2007. A generalized analysis of hydrophobic and loop clusters within globular protein sequences. BMC Struct Biol 7:2. http://dx.doi.org/10.1186/1472-6807-7-2.
63. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389-3402. http://dx.doi.org/10.1093/nar/25.17.3389.
64. Buchan DW, Minneci F, Nugent TC, Bryson K, Jones DT. 2013. Scalable web services for the PSIPRED protein analysis workbench. Nucleic Acids Res 41:W349-W357. http://dx.doi.org/10.1093/nar/gkt381.